Parkinson's disease

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

Retrieved on: 
Thursday, April 4, 2024
Deep, Transcranial magnetic stimulation, Brainsway, Medicine, Parkinson's disease, PD, Patient, Research, Quality of life, FDA, Pharmaceutical industry

The paper was published in Frontiers of Human Neuroscience, a leading peer-reviewed journal focused on advancing the understanding of brain mechanisms in both healthy and diseased states.

Key Points: 
  • The paper was published in Frontiers of Human Neuroscience, a leading peer-reviewed journal focused on advancing the understanding of brain mechanisms in both healthy and diseased states.
  • The review summarizes data from six different studies involving an aggregate total of 220 patients, including a substantial number of patients who were administered a two-stage Deep TMS protocol addressing prefrontal and motor targets.
  • "This clinical review marks an important step forward in our understanding of the potential benefits of Deep TMS for those suffering from Parkinson's Disease,” said Colleen Hanlon, Ph.D., Vice President of Medical and Clinical Affairs at BrainsWay.
  • BrainsWay Deep TMS is not cleared by the FDA as a safe and/or effective treatment for Parkinson's Disease.

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Retrieved on: 
Wednesday, April 3, 2024
Ventricular septal defect, DCN, Disease, HIV, Patient, CTD, Connective tissue disease, Death, Parkinson's disease, Imatinib, IND, Pulmonary hypertension, Woman, Therapy, Heart, Safety, Division, WHO, HIV/AIDS, Stomach, PAH, FDA, Blood, Food, Pharmaceutical industry

The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes.

Key Points: 
  • The meeting will be held on April 5, 2024, with meeting results to be reported following receipt of the formal meeting minutes.
  • “Following our pre-NDA discussion with the FDA related to the path to approval for IkT-001Pro in up to 11 blood and stomach cancers in January, we requested an additional FDA meeting with the Division of Cardiology and Nephrology to discuss Pro as a treatment for Pulmonary Arterial Hypertension,” said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase.
  • “PAH is a rare condition that primarily afflicts women between the ages of 30 and 60 and can lead to premature heart failure and death.
  • We believe that Pro may be a be a safer and better tolerated therapeutic option for imatinib treatment in PAH.

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Wednesday, March 27, 2024
Research, Neurodegenerative disease, Notifiable disease, LDL, Obesity, University, Comparison, PCSK9, Central Florida, Translational research, COVID-19, PD, CSF, Diabetes, Amprion, Patient, CNS, Mayo Clinic, Vaccine, Journal, Biomarker, Travel, Myostatin, Hope, SARS-CoV-2, D&O, Investment, Solid lipid nanoparticle, MDS, Marketing, Parkinson's disease, Hypercholesterolemia

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • We also seek to advance UB-311, our anti-Aβ Alzheimer’s candidate, as we resume dialogue with regulatory authorities and partners.
  • General and administrative expenses were $3.4 million and $7.7 million for the three months ended December 31, 2023, and 2022, respectively.
  • General and administrative expenses were $22.4 million and $28.4 million for the years ended December 31, 2023, and 2022, respectively.

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Retrieved on: 
Tuesday, April 9, 2024
Psilocybin, Alzheimer's disease, Partnership, Research, Parkinson's disease, Inflammatory bowel disease, Therapy, Intellectual property, Bryostatin, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul").
  • Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics.
  • Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion—Israel Institute of Technology ("the Technion").
  • Synaptogenix, through its partnership with Cannasoul, expanded its stake in PsygaBio, enabling Synaptogenix Chairman Josh Silverman and Director Bruce Bernstein to join PsygaBio's board of directors.

Pacing Toward Progress: Dr. Daniel Corcos' Trailblazing Research Reveals Exercise's Potential to Slow Parkinson's Disease Progression

Retrieved on: 
Monday, April 8, 2024
Exercise, Disease, PD, Alzheimer's disease, Risk, Patient, Heart rate, State, Observation, Parkinson's disease, Woman, Cognition, Principal investigator, Urban, Neurodegenerative disease, Pharmaceutical industry

As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.

Key Points: 
  • As the second-most common neurodegenerative disease after Alzheimer's disease, PD affects nearly 90,000 individuals annually in the U.S. Globally, over 10 million people are grappling with PD.
  • Moreover, men are 1.5 times more likely to develop Parkinson's disease than women.
  • Three recent studies, suggests that endurance exercise may offer a significant breakthrough in Parkinson's treatment in that the suggest that exercising at 80% of maximum heart rate may slow disease progression.
  • Dr. Corcos underscores the indispensable role of aerobic exercise in Parkinson's treatment, citing evidence suggesting its potential to slow disease progression.

Precision Neuroscience Expands Clinical Research In Brain–Computer Interface

Retrieved on: 
Friday, March 22, 2024
Brain, BCI, Motor cortex, Assistant, Associate, Partnership, University, Patient, Deep brain stimulation, DSM-IV codes, Research, Sale, Electrode, Parkinson's disease, Trial of the century, Behavior, Hospital, Optimism, Precision, DBS, Mount Sinai Health System, Movement, Hand, Health, Medical device

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).
  • Its design allows for safe implantation and removal by neurosurgeons without causing harm to delicate brain tissue.
  • Dr. Ben Rapoport, Chief Science Officer and co-founder of Precision Neuroscience, underscored the significance of these studies in advancing both medical science and patient care.
  • This partnership aims to explore the diverse applications of high-resolution cortical surface arrays in clinical settings, ranging from intraoperative monitoring to neurocritical care.

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Quarter, Annual report, Medical Products Agency (Sweden), Parkinson's disease, General counsel, International, Patient, Loan agreement, Research, Webcast, Form 10-K, University, Stock, Senior, Bank statement, TSX, SKU, Investment, Pet, Cryptocurrency

SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023.

Key Points: 
  • SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2023.
  • Net comprehensive loss was $1.7 million, down from $2.3 million in the fourth quarter of 2022.
  • Operating costs and expenses were $2.4 million for the fourth quarter of 2023, versus $2.7 million for the corresponding three-month period of 2022.
  • IntelGenx will host a conference call to discuss these 2022 fourth quarter and full year financial results today at 8:30 a.m.

Baptist Health Foundation Announces Historic $50 Million Gift from Kenneth C. Griffin

Retrieved on: 
Tuesday, March 19, 2024
Citadel, Epilepsy, Baptist Health, Neurology, Baptist Health South Florida, Science, Alzheimer's disease, Incidence, Patient, Research, History, Neuroscience, Parkinson's disease, Baptists, DSM-IV codes, Hospital, Baptist Hospital, Physician, Health, Dementia, Medicine, Pharmaceutical industry

Miami, FL, March 19, 2024 (GLOBE NEWSWIRE) -- Baptist Health Foundation today announced the largest single donation in the nearly 65-year history of Baptist Health South Florida.

Key Points: 
  • Miami, FL, March 19, 2024 (GLOBE NEWSWIRE) -- Baptist Health Foundation today announced the largest single donation in the nearly 65-year history of Baptist Health South Florida.
  • The $50 million gift from Kenneth C. Griffin, founder and CEO of Miami-based hedge fund Citadel and founder of Griffin Catalyst, will advance neurological care in the region.
  • The new Kenneth C. Griffin Center at Miami Neuroscience Institute will also help advance research related to neuroscience and neurodegenerative disorders.
  • “This extraordinary gift is a visionary contribution to the well-being of current and future generations in South Florida and beyond,” said Bo Boulenger, president and CEO of Baptist Health.

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

Retrieved on: 
Monday, March 18, 2024
EEG, U.S. FDA, Schizophrenia, Deficit spending, Data analysis, Memory, Alzheimer's disease, Central nervous system, Part, Delusion, Patient, CNS, ERP, Biomarker, Doctor of Philosophy, Parkinson's disease, Quality of life, Personalized medicine, Life, Trial of the century, Positive, Rett syndrome, Hallucination, PANSS, Therapy, SIGMAR1, DSM-IV codes, FDA, Pharmaceutical industry

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.

Key Points: 
  • “Initiating our Phase 2 trial of ANAVEX®3-71 in schizophrenia ahead of schedule is a testament to the hard work and dedication of our clinical study team,” stated Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
  • “Schizophrenia is a challenging disorder that can impair social and occupational functions and overall quality of life for the nearly 24 million people affected worldwide.
  • The placebo-controlled Phase 2, two-part, in-patient trial, ANAVEX®3-71-SZ-001 ( NCT06245213 ), will investigate the effects of ANAVEX®3-71 in patients with schizophrenia.
  • In addition to the electrophysiological biomarkers, Anavex is applying novel neuroinflammatory, metabolomic, and transcriptomic biomarkers at the intersection of schizophrenia pathophysiology and ANAVEX®3-71’s novel, dual mechanism of action.

Rumble Boxing Joins the Fight with The Michael J. Fox Foundation

Retrieved on: 
Wednesday, April 3, 2024
Philanthropy, Health, Sports, Neurology, Fitness & Nutrition, Boxing, Foundation, PDT, Disease, Partnership, Research, Perspiration, MJFF, Introduction, Fitness, Parkinson's disease, House, Courage, DSM-IV codes, HIIT, Rumble, Multimedia

Rumble Boxing , an Xponential Fitness brand, announced today its continued partnership for the second consecutive year with Team Fox, the grassroots fundraising community of The Michael J.

Key Points: 
  • Rumble Boxing , an Xponential Fitness brand, announced today its continued partnership for the second consecutive year with Team Fox, the grassroots fundraising community of The Michael J.
  • Fox Foundation for Parkinson’s Research (MJFF) to raise funds and garner support for Parkinson’s Awareness Month in April.
  • To amplify the impact, Rumble Boxing is excited to present a multi-city panel tour with Rumble Boxing Co-Founder, Noah Neiman, alongside MJFF community members affected by Parkinson’s.
  • With over 80 studios nationwide, Rumble Boxing pairs boxing, HIIT, metabolic conditioning, and strength training group fitness for a full-body workout for all fitness levels.